{"product_id":"reckitt-swot-analysis","title":"Reckitt Benckiser Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eReckitt Benckiser’s resilient brand portfolio and global distribution give it clear strengths, while regulatory scrutiny and input-cost pressures pose notable risks; emerging health and hygiene trends offer growth avenues but intensifying competition could squeeze margins—discover the full picture with our complete SWOT analysis, a professionally written, editable report (Word + Excel) ideal for investors, strategists, and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResilient Portfolio of Global Powerbrands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReckitt’s portfolio of global powerbrands—Dettol, Lysol, Mucinex—delivered roughly 60% of group revenue in 2024, supporting strong margins and pricing power with brand-led market shares above 30% in core categories; brand loyalty helped organic sales growth of 4.5% in FY 2024 despite muted consumer spending. These leading positions create a stable revenue base through cycles, with emerging markets contributing ~45% of sales, reducing single‑market dependence and smoothing top‑line volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Position in Consumer Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpreckitt has shifted toward health-led growth with its consumer health segment delivering pro forma organic revenue of about and contributing roughly group adjusted operating profit driven by brands like gaviscon nurofen.\u003e\n\u003cpover-the-counter products carry higher gross margins reported group adjusted margin near in h1 versus lower household ebit conversion.\u003e\n\u003cpthis strategy matches long-term trends: global self-care market forecasted to reach by and aging populations in oecd countries supporting sustained demand for otc solutions.\u003e\n\u003c\/pthis\u003e\u003c\/pover-the-counter\u003e\u003c\/preckitt\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D and Innovation Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReckitt reinvests about 2.7% of 2024 revenue (≈£520m of £19.3bn) into R\u0026amp;D, keeping product differentiation via science-led health formulations and sustainable packaging innovations that support premium pricing; recent rollouts cut plastic by 30% in key SKUs and improved efficacy claims validated by third‑party trials in 2023–24. This R\u0026amp;D depth helps the portfolio track shifting consumer preferences and tighter safety\/regulatory standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReckitt’s sophisticated logistics reach over 190 countries via retail and digital channels, letting the company scale launches quickly and lower unit costs; in 2024 global net revenue was £13.9bn, supporting supply-chain leverage across markets.\u003c\/p\u003e\n\u003cp\u003eLongstanding retailer ties secure premium shelf space and promotions, evident in a 2024 emerging‑market growth of 6% and consistent global market‑share gains in health and hygiene categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e190+ countries reach\u003c\/li\u003e\n\u003cli\u003e£13.9bn 2024 net revenue\u003c\/li\u003e\n\u003cli\u003e6% 2024 emerging‑market growth\u003c\/li\u003e\n\u003cli\u003eRapid new‑product scale; lower unit costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Cash Flow and Financial Discipline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReckitt delivered free cash flow of about 2.1 billion pounds in FY 2024, enabling a 2024 dividend yield near 2.8% and continued share buybacks while cutting net debt by ~1.3 billion pounds.\u003c\/p\u003e\n\u003cp\u003eThe company keeps strict capital allocation, prioritising high-IRR projects and further deleveraging after the 2017 RB acquisition, giving a buffer against inflation and FX shocks and funding R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY24 free cash flow ~£2.1bn\u003c\/li\u003e\n\u003cli\u003eNet debt reduced ~£1.3bn (year)\u003c\/li\u003e\n\u003cli\u003eDividend yield ~2.8% (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: high-IRR capex, R\u0026amp;D, selective M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReckitt: Powerbrands Drive 60% of Sales, £2.1bn FCF and 4.5% Organic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReckitt’s global powerbrands (Dettol, Lysol, Mucinex) drove ~60% of 2024 revenue, supporting 4.5% organic growth and ~58% adjusted gross margin; Consumer Health grew ~7.6% organically and supplied ~45% of adjusted operating profit. FY24 free cash flow ~£2.1bn, net debt cut ~£1.3bn, R\u0026amp;D ≈2.7% of revenue (£520m). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePowerbrand share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic growth\u003c\/td\u003e\n\u003ctd\u003e4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003e~£2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Reckitt Benckiser Group, highlighting its core strengths, operational weaknesses, market opportunities, and external threats shaping strategic performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Reckitt Benckiser for rapid strategic alignment and executive briefings, enabling quick edits to reflect shifting market or product priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Exposure to Litigation Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReckitt faced major legal exposure from its 2017 Mead Johnson acquisition; NEC (necrotizing enterocolitis) lawsuits tied to infant formula could push aggregate settlements into the hundreds of millions — analysts cited potential liabilities \u0026gt;$500m in 2024—creating earnings volatility.\u003c\/p\u003e\n\u003cp\u003eLegal fees and provision increases hit margins: Reckitt booked £XXm in litigation-related charges in 2024 (company reports), weighing on investor sentiment and lowering valuation multiples as management focus shifts to courtroom strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Portfolio Restructuring Drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe ongoing divestment of essential home brands part reckitt benckiser group plc portfolio pruning has added operational complexity and risked short-term revenue leakage reported a organic net decline in h1 categories undergoing restructuring. while these moves aim to sharpen focus separation integration costs drove ebit volatility with operating margin down basis points year-on-year managing dozens across health hygiene nutrition ties up management bandwidth capex potentially diluting investment higher-growth segments like immune which grew faster at low-double-digit rates\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration Risk in Infant Nutrition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe nutrition segment shows concentration risk: infant nutrition fell 4.5% organic in FY2024 and accounted for ~14% of group sales, making overall results sensitive to demographic shifts and policy changes.\u003c\/p\u003e\n\u003cp\u003eBirth rates dropped 2–3% in key markets (China, Europe) in 2024, while US Enfamil faced 2022–23 supply disruptions and China saw rising local competition, pressuring margins.\u003c\/p\u003e\n\u003cp\u003eRegulatory scrutiny—stricter safety checks in China and import rules in 2024—adds volatility, so nutrition contributes unevenly to earnings quarter-to-quarter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlowing Growth in Hygiene Post-Pandemic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePost-COVID normalization cut Reckitt Benckiser Group’s (RB) hygiene growth to mid-single digits in 2024 vs peak pandemic rates; Lysol faced intensified competition as consumer sanitization urgency fell.\u003c\/p\u003e\n\u003cp\u003eRB increased brand and promotional spend in 2024, contributing to a 120 basis-point operating margin headwind in H1 2024 versus 2021 levels, pressuring short-term profitability.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eHygiene growth down to mid-single digits (2024)\u003c\/li\u003e\n\u003cli\u003e~120 bps margin pressure H1 2024 vs 2021\u003c\/li\u003e\n\u003cli\u003eHigher marketing spend to protect Lysol share\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Net Debt Levels from Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePast large-scale deals, notably the US$17.9bn Mead Johnson acquisition in 2017, left Reckitt with high net debt that needs active management to avoid balance-sheet strain.\u003c\/p\u003e\n\u003cp\u003eNet debt fell to about £3.9bn at end-2024 and debt\/EBITDA improved to ~1.8x, but interest expense—around £350m in 2024—still limits room for transformative M\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003eHigh leverage also raises sensitivity to global rate moves, increasing refinancing and FX risks if yields rise further.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMead Johnson cost: US$17.9bn\u003c\/li\u003e\n\u003cli\u003eNet debt ~£3.9bn (end-2024)\u003c\/li\u003e\n\u003cli\u003eDebt\/EBITDA ~1.8x (2024)\u003c\/li\u003e\n\u003cli\u003eInterest expense ~£350m (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegal risk, divestment hit and debt pressure cloud growth; NEC exposure \u0026gt;$500m\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWeaknesses: Legal exposure from NEC lawsuits (potential \u0026gt;$500m liability in 2024) and higher litigation costs erode margins; divestment of Essential Home brands caused 3% organic revenue decline and ~120bps EBIT volatility in H1 2025; nutrition concentration (infant nutrition ~14% sales, -4.5% organic FY2024) and lower hygiene growth (mid-single digits 2024) limit resilience; net debt ~£3.9bn, debt\/EBITDA ~1.8x (end-2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential NEC liability (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic rev decline (divestment areas H1 2025)\u003c\/td\u003e\n\u003ctd\u003e-3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfant nutrition FY2024\u003c\/td\u003e\n\u003ctd\u003e-4.5% \/ ~14% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHygiene growth (2024)\u003c\/td\u003e\n\u003ctd\u003eMid-single digits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (end-2024)\u003c\/td\u003e\n\u003ctd\u003e~£3.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/EBITDA (2024)\u003c\/td\u003e\n\u003ctd\u003e~1.8x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eReckitt Benckiser Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Reckitt Benckiser Group SWOT report you'll get; purchase unlocks the entire in-depth, editable version. You’re viewing a live preview of the actual file, structured for immediate use after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752481403257,"sku":"reckitt-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/reckitt-swot-analysis.png?v=1772241568","url":"https:\/\/matrixbcg.com\/products\/reckitt-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}